MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the 2025
pipe, net of series b...
$168,729,827
Net cash provided by
(used in) financing...
$168,299,452
Canceled cashflow
$430,375
Net increase
(decrease) in cash and cash...
$1,604,714
Canceled cashflow
$166,694,738
Principal payments of
notes payable
$275,849
Principal payments on
finance leases
$142,563
Tax payments for
share settlement of...
$11,205
Payment of deferred
issuance costs
$758
Sales and maturities
of investments
$21,262,086
Proceeds from the sale of
equipment
$500
Net income (loss)
$13,273,683
Stock-based compensation
expense
$5,210,647
Depreciation and
amortization
$2,994,763
Accounts payable
$1,482,793
Accrued expense and
other current...
$941,524
Write-off of deferred
issuance costs
$261,105
Amortization of finance
right-of-use assets
$86,823
Operating lease
right-of-use assets and...
-$67,420
Net cash used in
investing activities
-$121,706,130
Net cash used in
operating activities
-$44,775,111
Effect of exchange rate
changes on cash and cash...
-$213,497
Canceled cashflow
$21,262,586
Canceled cashflow
$24,318,758
Purchases of investment
securities
$142,035,560
Changes in fair value of
warrant liabilities
-$62,754,186
Purchases of equipment
$933,156
Prepaid expenses and
other current assets
$5,285,259
Accrued interest
receivable
$891,826
Accretion of discounts on
short-term investments
$88,631
Net realized and
unrealized gain on...
$73,967
Back
Back
Cash Flow
source: myfinsight.com
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)